Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOR03087 in Relapsed/Refractory Multiple Myeloma
DRKS00003145Phase 2Completed
- Sponsor
- MorphoSys AG
- Start
- Jul 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of felzartamab in multiple myeloma (MM), sponsored by MorphoSys AG. Started Jul 2011; status: completed.
02
Drugs
felzartamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on DRKS00003145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00003145.